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Abstract 
The 42 amino acid form of amyloid β (Aβ1-42) in cerebrospinal fluid (CSF) has been 
widely accepted as a central biomarker for Alzheimer's disease (AD). Several 
immunoassays for Aβ1-42 are commercially available, but can suffer from between 
laboratory and batch-to-batch variability and lack of standardisation across assays. 
As a consequence, no general cut-off values have been established for a specific 
context of use (e.g., clinical diagnostics) and selection of individuals for enrolment in 
clinical trials (patient stratification) remains challenging. 
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
has initiated a working group for CSF proteins (WG-CSF) to facilitate standardization 
of Aβ1-42 measurement results. The efforts of the IFCC WG-CSF include 
development of certified reference materials (CRMs) and reference measurements 
procedures (RMPs) for key biomarkers. 
Two candidate RMPs for quantification of Aβ1-42 in CSF based on liquid 
chromatography tandem mass spectrometry (LC-MS/MS) have been developed and 
tested in two ring trials. Furthermore, two commutability studies including native CSF 
pools, artificial CSF and spiked material have been completed. On the basis of these 
studies, human CSF pools containing only endogenous Aβ1-42 at three 
concentrations were selected as the format for future CRMs that are now being 
processed. 
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1. Introduction 
The 42 amino acid form of amyloid β peptide (Aβ1-42) in cerebrospinal fluid (CSF) is 
widely accepted as a key biomarker for Alzheimer's disease (AD) together with total 
tau (T-tau) and phosphorylated tau (P-tau) protein (1). The decrease of Aβ1-42 levels 
in CSF reflects its deposition into amyloid plaques in the brain (2), that is one of the 
hallmarks of the disease. The CSF levels of Aβ1-42 have been shown to exhibit high 
diagnostic accuracy for AD dementia (3) and prodromal AD (4-7). Furthermore, CSF 
Aβ1-42 levels show high concordance with amyloid positron emission tomography 
(PET) scans (8). What makes this biomarker particularly useful for early diagnosis is 
the fact that it is the first one that shows changes, many years before onset of clinical 
symptoms. Current clinical routine measurement procedures are based on enzyme-
linked immunosorbent assays (ELISA) or immunoassays on other technology 
platforms. Marked variability in measurement values was observed between 
analytical procedures and between laboratories (7). For this reason, the Alzheimer’s 
Association Quality Control (QC) program was initiated among members of the 
Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) (9). 
Although the QC program has been active for several years, variability between 
routine measurement procedures is still a problem due to lack of standardisation. 
This variability is partly due to differences in laboratory procedures for sample 
collection, storage and analysis, as well as variability linked to the manufacturing 
process for the assays resulting in batch-to-batch variations. However the lack of 
standardisation is the main reason for which different immunoassays give different 
concentrations when measuring the same sample (10). The availability of a 
commutable certified reference material (CRM) could dramatically decrease the 
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variability of measurement results, specifically batch-to-batch variability and the bias 
between assays. 
Since the AD research field has gone through a thorough validation process to 
ascertain biologic and diagnostic relevance of the CSF biomarkers, the International 
Federation of Clinical Chemistry and Laboratory Medicine (IFCC) approved the setup 
of a working group on CSF proteins (WG-CSF) with the goal of developing reference 
systems for CSF biomarker measurements. The immediate tasks of the IFCC WG-
CSF included the collection of human CSF for the production of a commutable CRM 
and the establishment of reference measurement procedures (RMPs). Although the 
activities are not limited to the standardization of CSF Aβ1-42 measurements, this 
analyte was chosen first as a timely development of RMPs seemed more feasible 
(11). These developments happened at an opportune moment as the first promising 
results of clinical trials have been reported (12, 13) and there was an increased need 
to select individuals at early stages to enrol them in clinical trials and adapt current 
diagnosis criteria and clinical guidance. The Institute for Reference Materials and 
Measurements (JRC-IRMM), which is one of the seven European Commission's 
Joint Research Centres, assists the WG-CSF in these efforts with advice on 
standardisation and by producing the first CRM for CSF Aβ1-42 according to the 
International Organisation for Standardisation (ISO) Guide 34:2009 (14). 
The aim of standardisation is to create measurement results for the same sample 
produced over time, by different laboratories or with different routine measurement 
procedures that are equivalent within their corresponding uncertainties (15, 16). This 
requires the setup of a calibration hierarchy that allows traceability of measurement 
results to a higher order measurement standard (Figure 1A). The first concern in the 
standardisation of Aβ1-42 is the evaluation of the degree of correlation between 
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routine measurement procedures. Comparability of measurement results can only be 
achieved if results from different routine measurement procedures correlate. Next, 
the upper part of the calibration hierarchy needs to be built up (Figure 1B). This 
includes the development of a RMP that provides results that correlate with routine 
measurement procedures and a matrix CRM that is commutable for the intended 
routine measurement procedures. This paper describes the progress achieved and 
the difficulties encountered in setting up a reference system for Aβ1-42. 
 
2. Reference measurement procedures for CSF Aβ1-42  
The development and validation of one or more RMPs is a crucial step towards the 
development of a CRM and the standardisation of biomarker measurements. The 
RMPs are not only useful to assess the performance of other measurement 
procedures and assign values to routine calibrators, but are also necessary for value 
assignment of candidate CRMs. In recent years liquid chromatography tandem mass 
spectrometry (LC-MS/MS) has been increasingly used for the quantification of 
biomarkers and several LC-MS/MS methods for the quantification of CSF Aβ1-42 
have been reported in the literature (17-19). This indicated that the development and 
validation of a LC-MS/MS-based RMP should be feasible. One of the methods (19) 
has been used in the two commutability studies reported in section 3 of this report. 
Results from this method showed good correlation with those from routine 
measurement procedures (Figure 2). The bias (slope ≠ 1) that can be observed is 
likely due to differences in calibration, which could easily be removed by calibration 
with a common calibrant. Since then, two RMPs for the quantification of CSF Aβ1-42 
based on LC-MS/MS have been developed and submitted to the JCTLM on behalf of 
the WG-CSF. Both methods are based on a procedure published by Lame et al. (18) 
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that uses guanidine hydrochloride treatment followed by a solid phase extraction 
step as sample preparation and multiple reaction monitoring for quantification. The 
two RMPs use the same sample preparation, but they differ in instrumentation and 
more importantly in the matrix used for preparing the calibration solutions. The 
method developed by Leinenbach et al. (20) (RMP1) uses human CSF as calibrator 
matrix spiked with 15N-labelled Aβ1-42 peptide, as a surrogate analyte, whereas the 
second method described by Korecka et al. (21) (RMP2) uses calibrators prepared 
from artificial CSF (aCSF) containing 4 mg/mL BSA, as a surrogate matrix, spiked 
with recombinant Aβ1-42 peptide (Table 1). Despite the differences, the results of the 
two RMPs correlate very well (R2 = 0.98) as shown in Figure 3. 
 
2.1 LC-MS/MS ring trial 1 
A ring trial was organized in collaboration with the GBSC to evaluate the correlation 
between results from different LC-MS/MS methods for the quantification of Aβ1-42 
and to estimate the inter-laboratory variability for those methods. The following four 
laboratories that are involved in the GBSC participated: University of Gothenburg, 
University of Pennsylvania, Waters Corporation (Milford, MA, USA) and PPD 
(Richmond, VA, USA). Each laboratory received 12 human CSF pools (Clinical 
Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden) and 
was asked to use their validated in-house method to quantify Aβ1-42. In addition to 
that, the INNOTEST β-AMYLOID (1-42) assay (Fujirebio-Europe, Inc., Ghent, 
Belgium) was used to analyse the correlation of the LC-MS/MS methods to a routine 
immunoassay measurement procedure. The details of this study have been reported 
elsewhere (22). In short, all laboratories used the same sample preparation scheme, 
and while all applied selected reaction monitoring (SRM) for LC-MS/MS 
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quantification, different instrumentation and calibration methods were used. The 
results of all methods correlated well (R2 = 0.98) with high analytical precision and an 
average intra-laboratory coefficient of variation (CV) of 4.7 %. Furthermore, they 
showed good correlation with the selected routine measurement procedure. 
However, the average inter-laboratory CV was 12.2 %, which was not surprising as 
no common calibrator was available at the time of the study. Therefore, one CSF 
sample was selected as reference sample, a correction factor was calculated and 
when applied the inter-laboratory variability was reduced by 32 % to a CV of 8.3 %. 
 
2.2 LC-MS/MS ring trial 2 
A second LC-MS/MS ring trial was initiated to investigate how a common Aβ1-42 
calibrator could be used in a ring trial and by how much its use could reduce the 
inter-laboratory variability. This was an important step, since the value assignment of 
the candidate CRMs is foreseen to be done by LC-MS/MS using a common Aβ1-42 
calibrator. The JRC-IRMM produced a calibrator based on a procedure adapted from 
Broersen et al. (23) that contained recombinant Aβ1-42 peptide (rPeptide, Bogart, GA, 
USA) in 20 % acetonitrile and 1 % ammonium hydroxide in water. The calibrator was 
provided to the participating laboratories (University of Gothenburg, University of 
Pennsylvania, Waters Corporation (Milford, MA, USA), PPD (Richmond, VA, USA) 
and Roche Diagnostics GmbH (Penzberg, Germany)) along with one aliquot of 20 
individual CSF samples (Clinical Neurochemistry Laboratory, Sahlgrenska University 
Hospital, Mölndal, Sweden). Each lab was instructed to use the common calibrator 
with their validated in-house method as well as with a common protocol for the 
preparation of calibrators provided by JRC-IRMM. An initial analysis of the data 
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received from the participating laboratories showed good correlation of the methods 
and an inter-laboratory CV of 9 % (manuscript in preparation). 
 
3. Commutability studies 
One crucial step in the development of a CRM is the assessment of its 
commutability, which has been defined by the Clinical and Laboratory Standards 
Institute (CLSI) as "the equivalence of the mathematical relationships among the 
results of different measurement procedures for a reference material and for 
representative samples of the type intended to be measured" (24). In other words, a 
reference material is commutable if it behaves in the same way as representative 
clinical samples. This material property is required for a material to be used for 
calibration and trueness control to assure accurate clinical results. Laboratory 
medicine applications like this usually require that a matrix reference material is 
developed, rather than a pure substance material. Matrix CRMs are often more 
demanding and expensive to produce, but much more likely to be commutable in 
clinical routine assays than a pure protein solution. In addition to that, spiking of 
native sample pools with the analyte is often performed to create the desired 
concentration level(s). Two commutability studies were conducted to select the most 
suitable starting material for the production of a commutable CRM for Aβ1-42. The 
details of those were previously reported elsewhere (25). 
 
3.1 Commutability study 1 
The first commutability study was organized to evaluate which matrix format would 
be most suited for the development of a reference material for Aβ1-42. The following 
five immunoassay-based routine measurement procedures were used: 1) MSD® 96-
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Well MULTI-ARRAY® Human (4G8) Abeta42 Ultra-Sensitive Kit (Meso Scale 
Discovery, Gaithersburg, MD, USA), 2) Human β Amyloid(1-42) ELISA Kit Wako 
High-Sensitive (Wako Pure Chemical Industries, Ltd., Osaka, Japan), 3) Human 
Amyloid β (1-42)(N) assay kit - IBL (Immuno-Biological Laboratories Co., Ltd., 
Fujioka, Japan, distributed by IBL International GmbH), 4) INNOTEST® β-AMYLOID 
(1-42) and 5) INNO-BIA AlzBio3 (both Fujirebio-Europe, Inc., Ghent, Belgium). In 
addition to that, a LC-MS/MS method was applied to compare the results to those 
obtained with the routine measurement procedures. A total of 48 individual CSF 
clinical samples (Clinical Neurochemistry Laboratory, Sahlgrenska University 
Hospital, Mölndal, Sweden) and 16 candidate CRM formats were tested. The 
candidate CRM formats included native CSF pools with low and high intrinsic Aβ1-42 
concentrations as well as aCSF and PBS containing recombinant Aβ1-42 (rPeptide, 
Bogart, GA, USA). Furthermore, all four matrices were spiked with different 
concentrations of recombinant Aβ1-42 peptide and the addition of the detergent 
Tween® 20 (Sigma-Aldrich, St. Louis, MO, USA) was tested. The study showed that 
most of the measurement procedures selected produced highly correlated results 
(Figure 4), but also showed that different routine measurement procedures gave 
results that varied up to a factor 2.6. This is consistent with previously published data 
(26) and a problem that can be solved with the use of a commutable CRM for 
calibration. The neat CSF pools behaved like the individual CSF clinical samples for 
most method combinations, but none of the artificial matrices (aCSF and PBS) 
tested in the study were commutable for all method combinations tested (Figure 5A). 
The addition of detergent did not improve the results and even caused the native 
CSF pools to be non-commutable for some method combinations. The conclusion of 
this study was that a native CSF pool should be used for the production of the CRM. 
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3.2 Commutability study 2 
A second commutability study was organized to investigate 1) if the foreseen CSF 
pool would be suitable for the production of the CRMs and 2) if spiking the native 
CSF pool with recombinant Aβ1-42 was an option to create the desired concentration 
levels of commutable CRM and construct calibration curves. For this study eight 
routine measurement procedures and one LC-MS/MS method were used to measure 
32 individual CSF clinical samples (Clinical Neurochemistry Laboratory, Sahlgrenska 
University Hospital, Mölndal, Sweden), which covered the clinical spectrum of Aβ1-42 
values. The following routine measurement procedures were included in the study: 
1) MSD® 96-Well MULTI-SPOT® Human Aβ42 V-PLEX Kit (Meso Scale Discovery, 
Gaithersburg, MD, USA), 2) Amyloid-beta (1-42) CSF ELISA (IBL International 
GmbH, Hamburg, Germany), 3) VITROS® Immunodiagnostic Amyloid Beta 42 Assay 
(AB-42) (Saladax Biomedical, Bethlehem, PA, USA), 4) Elecsys® β-Amyloid (1-42) 
immunoassay (Roche Diagnostics, Penzberg, Germany) (27), 5) EUROIMMUN 
Beta-Amyloid (1-42) (EUROIMMUN, Lübeck, Germany), 6) INNO-BIA AlzBio3 
(Fujirebio-Europe, Ghent, Belgium), 7) INNOTEST® β-AMYLOID (1-42) (with ready-
to-use calibrators, Fujirebio-Europe), and 8) Simoa Human Aβ42 (Quanterix 
Corporation, Lexington, MA, USA). To create the CRM candidates, a total of 24 
individual CSF clinical samples (Clinical Neurochemistry Laboratory, Sahlgrenska 
University Hospital, Mölndal, Sweden) foreseen for the production of the CRM were 
combined to produce a test pool with a final Aβ1-42 concentration of around 760 ng/L 
(value determined with INNOTEST β-AMYLOID (1-42)). Additionally, the neat CSF 
pool was spiked with the recombinant Aβ1-42 calibrator solution prepared by JRC-
IRMM to reach Aβ1-42 spiking concentrations of 300 ng/L, 800 ng/L, and 1300 ng/L. 
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The results showed that the native CSF pool was again commutable for almost all 
method combinations (Figure 5B). However, the spiked levels were only commutable 
for some method combinations, with the lower spike level being commutable for 
more method combinations than the highest spike level. The results of the study 
clearly showed that only a native CSF pool would be most suitable for the production 
of a commutable CRM. Furthermore, it indicated that spiking the native CSF pool 
with recombinant Aβ1-42 peptide would not be an option to create multi-level 
calibrators for the calibration of current routine measurement procedures. 
 
4. Production of candidate CRMs for CSF Aβ1-42 
Since the first commutability study indicated that only a native CSF pool would be 
suitable as a CRM, the Clinical Neurochemistry Laboratory at Sahlgrenska University 
Hospital in Mölndal, Sweden collected a sufficiently large volume of CSF (de-
identified samples according to Swedish Law on Biobanks in Healthcare (2002:297)) 
from 24 individuals with normal pressure hydrocephalus for the production of a 
candidate CRM. The production of the CRM is done by the JRC-IRMM according to 
ISO Guide 34:2009 (14). Although the initial planning foresaw the production of a 
single Aβ1-42 CRM, the outcome of the second commutability study urged a change 
in planning. Since spiking the native CSF pools with recombinant Aβ1-42 resulted in 
non-commutable candidate CRM formats, this approach could not be used to 
construct multi-level calibration curves to calibrate routine measurement procedures. 
Therefore, the decision was taken to produce three candidate CRMs with different 
Aβ1-42 concentrations that could be mixed with each other. The clinical samples 
initially selected for the production were subsequently divided to create three CSF 
pools with Aβ1-42 concentrations at the low and high end of the clinical range as well 
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as one close to the expected cut-off. In the meantime, the JRC-IRMM performed 
several feasibility studies to evaluate different manual and automated processing 
conditions as well as freezing procedures. For these studies, aCSF spiked with 
recombinant Aβ1-42 and human CSF were used. Samples of the filling were analysed 
by Roche Diagnostics with the Elecsys β-Amyloid (1-42) immunoassay (27). Several 
issues concerning the homogeneity of the filled materials with regard to the 
concentration of Aβ1-42 were encountered. Once the appropriate processing and 
freezing conditions were determined, the three CSF pools were processed. The vials 
were frozen at -70 ˚C and a required one-year stability monitoring started. The 
homogeneity of the candidate CRMs was evaluated by Roche Diagnostics with the 
Elecsys β-Amyloid (1-42) immunoassay and by ADx NeuroSciences with the 
EUROIMMUN Beta-Amyloid (1-42) assay. The results showed a between unit 
heterogeneity (ubb) below 1.5 % for all three levels. This value is calculated with an 
ANOVA on results from triplicate measurements on a set of samples, and does not 
include the contribution from method repeatability. The next step is the value 
assignment of the candidate CRMs, which is currently being organized. 
 
5. Next steps 
The next steps in the characterisation of the candidate CRMs include the value 
assignment. The proposed calibration hierarchy has been defined early in the 
development of the project and was already mentioned in paragraph 1. In principle, a 
CRM can be value assigned using either immunoassays or the RMPs based on LC-
MS/MS (28). In the case of Aβ1-42 the use of immunoassays for value assignment is 
not possible, since a calibrator that is commutable for all methods is very hard to 
produce. Therefore, the RMPs will be used for the value assignment. 
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Some challenges remain related to the characterisation of the Aβ1-42 calibrator, which 
was used in the second LC-MS/MS ring trial mentioned in paragraph 2.2. A 
combination of purity assessment and amino acid analysis (AAA) is used to assign a 
value and an uncertainty to the calibrator. However, the AAA of Aβ1-42 is more 
challenging than expected. While results for individual amino acids showed low CVs, 
large variability for the results between different amino acids was observed. One 
explanation could be the presence of peptide contaminations rich in certain amino 
acids or the presence of free amino acids. However, purity assessment of the 
calibrator by high-resolution LC-MS/MS did not confirm that suspicion. Another 
potential explanation could be that the peptide is not fully digested using the 
conditions selected. Consequently, additional effort is needed to investigate the 
source of the variability. 
The second LC-MS/MS ring trial using the common calibrator, showed that the 
candidate RMPs can be used for value assignment of the reference materials. Thus, 
once the calibrator is fully characterised, value assignment using the RMPs should 
lead to a certified value with appropriate uncertainties. 
Another question that needs to be addressed is the use of the CRMs for calibration 
of immunoassays. Preferably procedures should be developed for the transfer of 
values from the CRMs to (possibly non-commutable) in-house calibrators and kit 
calibrators in such a manner that results for clinical samples will be equivalent.  
 
6. Conclusion 
The WG-CSF has accomplished several important milestones essential for the 
development and release of a reference system for CSF Aβ1-42. Since the initiation of 
the working group, two RMPs for CSF Aβ1-42 based on LC-MS/MS quantification 
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have been developed and submitted to the JCTLM for listing them as ISO 
15193:2009 compliant methods. The correlation of different LC-MS/MS methods 
used for the quantification of CSF Aβ1-42 has been investigated in a ring trial, which 
showed that results of these methods have high analytical precision and are highly 
correlated. A second LC-MS/MS ring trial has almost been completed to scrutinise 
the use of a common Aβ1-42 calibrator for the envisioned value transfer to the 
candidate CRMs. In addition to that, several potential candidate CRM formats were 
tested in two commutability studies, which helped determine the most suitable format 
for the CRM. Since then, the raw material for the production of the candidate CMRs 
has been collected and several feasibility studies performed which helped to 
determine the most appropriate processing condition for the production of the final 
candidate CRMs. The three candidate CRMs have been produced by the JRC-IRMM 
and the homogeneity assessment showed low between unit heterogeneity. With 
these steps accomplished, the release of three CRMs for CSF Aβ1-42 is well 
underway, which will enable standardisation of this important measurand. 
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Tables 
Table 1. Comparison of reference measurement procedures for Aβ1-42 
 RMP1 (20) RMP2 (21) 
Calibrator [15N]Aβ1-42: 150-4000 ng/L Aβ1-42: 100-3000 ng/L 
Internal 
standard 
[13C]Aβ1-42: 1600 ng/L [15N]Aβ1-42: 1 ng/mL 
CSF Volume 180 µL 100 µL 
Calibrator 
matrix 
human CSF aCSF + 4 mg/mL BSA 
LC Thermo UltiMate 3000 Waters ACQUITY; 2D 
trapping/eluting 
Dilution 
Injection 
N/A 50 µL + 50 µL H2O (25 µL) 
LC eluents A: 5 % ACN, 0.075% NH4OH 
B: 95 % ACN, 0.025% NH4OH 
A: 0.1 % NH4OH 
B: 70 % ACN, 25 % MeOH, 5 
% TFE 
Column Thermo ProSwift RP-4H 
1.0 x 250 mm, 50 °C 
Waters BEH 300 
2.1 x 150 mm, 60 °C 
MS Thermo Scientific Q-Exactive Waters Xevo TQ-S  
Aβ1-42 range 150-4000 ng/L 100-3000 ng/L 
Abbreviations: CSF, cerebrospinal fluid; aCSF, artificial cerebrospinal fluid; BSA, 
bovine serum albumin; LC, liquid chromatography; ACN, acetonitrile; MeOH, 
methanol; TFE, trifluoroethanol; MS, mass spectrometer. 
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Figures 
 
 
Figure 1. (A) Overview of the traceability chain for Aβ1-42, linking results of routine 
samples to the international system of units (SI) as a common reference. (B) Steps 
necessary to establish the upper part of the traceability chain. Abbreviations: RMP, 
reference measurement procedure; CRM, certified reference material; SI, 
A 
B 
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International System of Units (Système International d'Unités); IVD, in vitro 
diagnostic. 
 
Figure 2. Correlation of the average results of CSF samples measured in duplicate 
with a LC-MS/MS method and a representative routine measurement procedure. 
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Figure 3. Correlation of the results of 10 CSF pools measured with the 2 reference 
measurement procedures (RMPs) for Aβ1-42 quantification by LC-MS/MS. Over the 
course of 3 days, 2 aliquots per CSF pool were measured in duplicate. Both methods 
were calibrated with a common Aβ1-42 calibrator provided by JRC-IRMM. Error bars 
indicate standard deviations of the daily averages measured with RMP2. 
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Figure 4. Correlation of routine measurement procedures used in the (A) first and 
(B) second commutability study. 
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Figure 5. Linear regression with 95 % confidence band and 95 % prediction interval 
of data from (A) the first and (B) the second commutability study. The results of the 
first study showed that only native pools are commutable for all method 
combinations, but not artificial solutions. The second study showed that while CSF 
pools spiked with recombinant Aβ1-42 peptide can be commutable for a few method 
A 
B 
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combinations, they are not commutable for the majority of method combinations 
tested. 
